These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1520490)

  • 21. Bupivacaine inhibits COX-2 expression, PGE2, and cytokine production in endotoxin-activated macrophages.
    Huang YH; Tsai PS; Huang CJ
    Acta Anaesthesiol Scand; 2008 Apr; 52(4):530-5. PubMed ID: 18339158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of liposomal and polycationic transfection complexes with pulmonary surfactant.
    Ernst N; Ulrichskötter S; Schmalix WA; Rädler J; Galneder R; Mayer E; Gersting S; Plank C; Reinhardt D; Rosenecker J
    J Gene Med; 1999; 1(5):331-40. PubMed ID: 10738550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants.
    Findlay RD; Taeusch HW; David-Cu R; Walther FJ
    Pediatr Res; 1995 Jan; 37(1):26-30. PubMed ID: 7700730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surfactant inhibits cationic liposome-mediated gene transfer.
    Tsan MF; Tsan GL; White JE
    Hum Gene Ther; 1997 May; 8(7):817-25. PubMed ID: 9143907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular storage of surfactant and proinflammatory cytokines in co-cultured alveolar epithelium and macrophages in response to increasing CO2 and cyclic cell stretch.
    Dixon DL; Barr HA; Bersten AD; Doyle IR
    Exp Lung Res; 2008 Jan; 34(1):37-47. PubMed ID: 18205076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor production by human sarcoid alveolar macrophages.
    Bachwich PR; Lynch JP; Larrick J; Spengler M; Kunkel SL
    Am J Pathol; 1986 Dec; 125(3):421-5. PubMed ID: 3799813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colfosceril palmitate (Exosurf)--artificial surfactant for immature lungs.
    Drug Ther Bull; 1991 Jun; 29(12):46. PubMed ID: 1935584
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of aerosolized artificial surfactant on repeated oleic acid injury in sheep.
    Zelter M; Escudier BJ; Hoeffel JM; Murray JF
    Am Rev Respir Dis; 1990 Apr; 141(4 Pt 1):1014-9. PubMed ID: 2327634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of cytokine release by alveolar macrophages treated with interleukin-4, interleukin-10, or transforming growth factor beta.
    Zissel G; Schlaak J; Schlaak M; Müller-Quernheim J
    Eur Cytokine Netw; 1996; 7(1):59-66. PubMed ID: 8704096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STAT1 antisense oligonucleotides attenuate the proinflammatory cytokine release of alveolar macrophages in bleomycin-induced fibrosis.
    Fan X; Wang Z
    Cell Mol Immunol; 2005 Jun; 2(3):211-7. PubMed ID: 16212889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of cytokine secretion by garlic oil derivatives is associated with suppressed nitric oxide production in stimulated macrophages.
    Chang HP; Huang SY; Chen YH
    J Agric Food Chem; 2005 Apr; 53(7):2530-4. PubMed ID: 15796590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitation of the alveolar distribution of surfactant mixtures in normal and injured lungs.
    Pataki G; Czopf L; Holm BA; Matalon S
    Am J Respir Cell Mol Biol; 1996 Oct; 15(4):451-9. PubMed ID: 8879178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic aerosols and airway secretions.
    Rubin BK
    J Aerosol Med; 1996; 9(1):123-30. PubMed ID: 10160202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of different surfactant preparations on bacterial growth in vitro.
    Neumeister B; Woerndle S; Bartmann P
    Biol Neonate; 1996; 70(2):128-34. PubMed ID: 8864432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of three surfactant preparations on in vitro lymphocyte functions.
    Woerndle S; Bartmann P
    J Perinat Med; 1994; 22(2):119-28. PubMed ID: 7965541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of modified natural or synthetic surfactant preparations on growth of bacteria causing infections in the neonatal period.
    Rauprich P; Möller O; Walter G; Herting E; Robertson B
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):817-22. PubMed ID: 10973461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility of exogenous surfactant to phospholipase A2 degradation.
    Duncan JE; Hatch GM; Belik J
    Can J Physiol Pharmacol; 1996 Aug; 74(8):957-63. PubMed ID: 8960386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perinatal pharmacology and cerebral blood flow.
    Saliba E; Autret E; Nasr C; Suc AL; Laugier J
    Biol Neonate; 1992; 62(4):252-7. PubMed ID: 1420623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exosurf treatment following wood smoke inhalation.
    Feldbaum DM; Wormuth D; Nieman GF; Paskanik M; Clark WR; Hakim TS
    Burns; 1993 Oct; 19(5):396-400. PubMed ID: 8216766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of human alveolar macrophage inflammatory cytokine production by interleukin-10.
    Thomassen MJ; Divis LT; Fisher CJ
    Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 1):321-4. PubMed ID: 8811054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.